China, Eli Lilly and Alzheimer's

Eli Lilly's Alzheimer's treatment approved in China (Dec. 17)
(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend approval for Biogen's drug, Leqembi, in paragraph 8) (Reuters) - China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's,
Global Health Advancements: Eli Lilly's Alzheimer's Treatment Gains Ground
The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in China, Merck's deal with Hansoh for a new obesity drug, impending HIV medication availability,
China Approves Lilly's Kisunla For Early Symptomatic Alzheimer's Disease Treatment
Eli Lilly and Co. (LLY) said that the National Medical Products Administration (NMPA) in China has approved Kisunla (donanemab-azbt,
Eli Lilly's Alzheimer's treatment approved in China
China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January, the company said late on Tuesday.
Eli Lilly Alzheimer's therapy approved in China
Eli Lilly (NYSE:LLY) announced Wednesday that China's National Medical Products Administration (NMPA) has approved its Alzheimer's treatment, Kisunla, making the country its fourth major market to approve the amyloid-targeting therapy.
Eli Lilly’s Kisunla Approved in China, Paving the Way for Innovative Alzheimer’s Treatment Options
China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a
Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout
What Eli Lilly (NYSE: LLY) is doing is far more impressive. While many investors may buy it for its growth potential, here's ...
24/7 Wall St6h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...
Eli Lilly: A Rare Buying Opportunity
Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...
15 Billion Reasons to Love Eli Lilly Stock Right Now
Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a ...
Kenosha News9h
Pleasant Prairie Plan Commission approves plans for Eli Lilly facility expansion
The Village of Pleasant Prairie Plan Commission on Monday approved the preliminary site and operational plans for the ...
Merck’s weight-loss pill deal: what it means for Eli Lilly
Merck announces a $2.0 billion agreement with Hansoh Pharma. The deal gives it rights to Hansoh's experimental weight-loss ...
Benefits Pro1d
Eli Lilly expands access to weight loss drug Zepbound
Eli Lilly headquarters located in Indianapolis, Indiana. Although the GLP-1 drug Zepbound has been shown to be effective ...
2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious
On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. In recent years, these two healthcare leaders ...